RedHill Biopharma's bowel syndrome drug study meets main goal

(Reuters) - RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome (IBS-D) met the main goal in a mid-stage study, with patients showing improvement in stool consistency.